Aaron Miller, MD
Neurology · New York, NYNPI 1598736811
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $195,299 of the $279,614 with a category attached, or 69.8%. 20 manufacturers reported payments, led by Biogen at 31.8% of the total. Reporting peaked in 2019 at $76,188 and has fallen 85.5% since, to $11,075 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $1391.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$89K
- Amgen$43K
- AstraZeneca$31K
- Adamas Pharmaceuticals, Inc.$23K
- Genentech USA, Inc.$17K
- Sanofi$15K
- plus $61K from 14 others
Across 41 payments — averaging $63,010 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.5M
- Mallinckrodt Enterprises LLC$24K
- Sanofi-aventis U.S. LLC$7K
- Mallinckrodt Hospital Products Inc.$5K
- F. Hoffmann-la Roche AG$5K
- Sanofi$4K
What the payments were for
- Consulting fees$57,42621%
- Speaking & faculty fees$195,29970%
- Travel & lodging$21,6998%
- Food & beverage$4,5592%
- Education$6310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 64 | $88,958 |
| Amgen | 33 | $43,182 |
| AstraZeneca | 25 | $31,417 |
| Adamas Pharmaceuticals, Inc. | 5 | $23,130 |
| Genentech USA, Inc. | 9 | $16,828 |
| Sanofi | 7 | $15,299 |
| EMD Serono, Inc. | 21 | $12,808 |
| Mylan Specialty L.p. | 5 | $12,209 |
| Mylan Institutional Inc. | 5 | $7,766 |
| Greenwich Biosciences, Inc. | 1 | $5,412 |
| Mylan Pharmaceuticals Inc. | 3 | $5,311 |
| AbbVie | 1 | $4,125 |
| Hexal AG | 1 | $3,575 |
| Janssen Global Services, LLC | 5 | $2,970 |
| Novartis | 6 | $2,892 |
| Bristol Myers Squibb | 5 | $2,646 |
| Banner Life Sciences, LLC | 2 | $913 |
| TG Therapeutics, Inc. | 1 | $113 |
| Genentech, Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$279,614 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 15 | $2,195 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.